Oncolytics Biotech(R) Announces the Presentation of REOLYSIN(R) Clinical Data at ESMO 2017 Congress
Additional randomized phase 2 data in metastatic breast cancer demonstrates doubling of overall survival in Hormone Receptor Positive (ER+PR+)/HER2- patients
Largest immuno-oncolytic virus safety database reported to-date demonstrates REOLYSIN® is s... Biopharmaceuticals, Oncology Oncolytics Biotech, REOLYSIN, breast cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Breast Cancer | Cancer | Cancer & Oncology | Databases & Libraries | HER2 | Hormones | Pharmaceuticals | Politics